Status:
RECRUITING
A Long-term Follow-up Study in Patients Who Received BEAM-101
Lead Sponsor:
Beam Therapeutics Inc.
Conditions:
Hemoglobinopathy
Sickle Cell Disease
Eligibility:
All Genders
14-37 years
Brief Summary
This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU ...
Detailed Description
Patients who were treated with BEAM-101 in Study BTX-AUT-001 will be asked to sign an informed consent form (ICF) to enter this LTFU study (during the EOS/Month 24 visit for BTX-AUT-001). Patients in ...
Eligibility Criteria
Inclusion Criteria:
- Have received BEAM-101 in Study BTX-AUT-001 and are in the process of completing that study's end-of-study (EOS) visit.
- Provide signed, written informed consent according to local institutional review board (IRB)/independent ethics committee (IEC) and institutional requirements.
Exclusion Criteria:
- There are no exclusion criteria for this study.
Key Trial Info
Start Date :
December 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 12 2043
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07373639
Start Date
December 15 2025
End Date
February 12 2043
Last Update
January 28 2026
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
Phoenix Children's Hospital
Phoenix, Arizona, United States, 85016
3
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224
4
Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston
Atlanta, Georgia, United States, 30329